Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: Significance for response to chemotherapy

被引:0
作者
Hu, ZB [1 ]
Minden, MD [1 ]
McCulloch, EA [1 ]
机构
[1] ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA
关键词
bcl-2; Ara-C; AML; ATRA; hydrocortisone; growth factors;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The blast stem cells of acute myeloblastic leukemia become more sensitive in culture to the chemotherapeutic agents cytosine arabinoside (Ara-C) and daunorubicin (DNR) when exposed to all-trans retinoic acid (ATRA) after drug. We have proposed that down regulation of bcl-2 by ATRA is part of the mechanism of sensitization. The hypothesis is based on reduced expression of bcl-2 mRNA, as seen in Northern blots, after ATRA. Nuclear run on experiments, however, failed to account completely for the effect at the transcriptional level, Accordingly, we looked for post-transcriptional effects of ATRA on bcl-2, using metabolic labelling of the protein to measure stability, We found that the half-life of bcl-2 protein is markedly shortened after treatment with ATRA. Hydrocortisone (HC) protects cells against the toxic effects of Ara-C or DNR when given before drug. HC does not alter bcl-2 expression at the level of mRNA; however, metabolic labelling shows that newly synthesized bcl-2 protein is stabilized in blast cells treated with HC. Response to Ara-C by growth factor responsive blast cells is influenced by the factor in the cultures; cells are more sensitive in cultures with G-CSF and less sensitive when GM-CSF is present. We compared two blast cell lines, OCl/AML-5, primarily responsive to GM-CSF, and OCl/AML-10, primarily responsive to G-CSF. Growth factor did not influence the stability of bcl-2 protein in either line. In contrast, Western blots showed that the amount of bcl-2 protein was greater in cultures with GMCSF or GM-CSF in combination with G-CSF than in cultures with G-CSF or no added factor. This pattern was seen regardless of the mitogenic response to G-CSF or GM-CSF. We interpret our findings as indicating that bcl-2 protein is transcriptionally activated; that the stability of the protein is decreased after ATRA and increased after HC; that the amount of bcl-2 protein is greater in cultures with GM-CSF than in cultures with G-CSF, regardless of which factor gives the greater mitogenic response. We propose that these post-transcriptional modifications of transcriptionally activated bcl-2 account, in part, for the regulation of drug sensitivity by ATRA, HC and growth factors.
引用
收藏
页码:410 / 416
页数:7
相关论文
共 50 条
  • [11] Clinical significance of P53 and Bcl-2 in acute myeloid leukemia patients of Eastern India
    Sahu, Geetaram
    Jena, Rabindra Kumar
    HEMATOLOGY REPORTS, 2011, 3 (03) : 91 - 94
  • [12] A concise review of BCL-2 inhibition in acute myeloid leukemia
    Yogarajah, Meera
    Stone, Richard M.
    EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (02) : 145 - 154
  • [13] Association of bcl-2, bax, bcl-xL and inteuleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
    Stoetzer, OJ
    Nussler, V
    Darsow, M
    Gullis, E
    PelkaFleischer, R
    Scheel, U
    Wilmanns, W
    LEUKEMIA, 1996, 10 : S18 - S22
  • [14] Generation of reactive oxygen intermediates after treatment of blasts of acute myeloblastic leukemia with cytosine arabinoside: Role of bcl-2
    Hedley, DW
    McCulloch, EA
    LEUKEMIA, 1996, 10 (07) : 1143 - 1149
  • [15] The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia
    Pollyea, Daniel A.
    Pei, Shanshan
    Stevens, Brett M.
    Smith, Clayton A.
    Jordan, Craig T.
    ANNUAL REVIEW OF CANCER BIOLOGY, VOL 5, 2021, 2021, 5 : 277 - 289
  • [16] Transcript-Level Dysregulation of BCL2 Family Genes in Acute Myeloblastic Leukemia
    Handschuh, Luiza
    Wojciechowski, Pawel
    Kazmierczak, Maciej
    Lewandowski, Krzysztof
    CANCERS, 2021, 13 (13)
  • [17] Bcl-2 expression and prognosis in childhood acute leukemia
    Tsurusawa, M
    Saeki, K
    Katano, N
    Fujimoto, T
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1998, 15 (02) : 143 - 155
  • [18] Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
    Wei, Yunxiong
    Cao, Yaqing
    Sun, Rui
    Cheng, Lin
    Xiong, Xia
    Jin, Xin
    He, Xiaoyuan
    Lu, Wenyi
    Zhao, Mingfeng
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [19] Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas
    Schneider, HJ
    Sampson, SA
    Cunningham, D
    Norman, AR
    Andreyev, HJN
    Tilsed, JVT
    Clarke, PA
    BRITISH JOURNAL OF CANCER, 1997, 75 (03) : 427 - 431
  • [20] Clinical efficacy and immune response of BCL-2 inhibitors combined with hypomethylating agents in the treatment of acute myeloid leukemia
    Peng, Xiaohuan
    Yu, Jianing
    Tang, Futian
    Li, Yanhong
    Bai, Jun
    Li, Lijuan
    Zhang, Liansheng
    DISCOVER ONCOLOGY, 2024, 15 (01)